Member Info for RuckRover

Inan,
No you can’t argue the case for “people”, you can only argue the case for yourself unless you are a mind reader who can read minds of people you can’t see.

The only reason you ever present for buying is the fact that you have and continue to do so.
I’m afraid that doesn’t make a sound case for investing.

Yes Ivy, I think 67% of shares in PI hands (from memory)
And whilst a lot of bought in the 20s-40s and are in for the long haul, there are a lot of investors who have bought in at a wide range of prices between 3.6p and 60p and for a wide variety of reasons. So someone who managed to buy in at under 4p, see it rise to 9p and then drop back to 5.5p May well get fed up and move on. Some may have bought in purely on the Covidity news and move on with a lack of any follow up.
So whilst we as LTH may not share these views, their actions have an impact on the SP.
Just a modest level of communication could have resulted in a higher SP than it is now.

Ray,
I think 99% of us here are unhappy about the lack of communication on Covid impact.
I think 100% of us know that Scancell cannot disclose anything they are not allowed to under NDA.

We are probably more split on the subject of research papers. We already have 4/5 platforms at various stages of development. I’d rather see some real progress on the ones we have already.
SCIB1 is the most clinically advanced but I get the feeling it isn’t going to be the first to produce some monetisation. So management focus has to be on selling/licensing something and getting the SCIB1 combo trial moving. A combination of products in the clinic and enough cash in the bank to see them through will work wonders for the SP.

Just the weigh in Bunsie, just the weigh in!

Inan, I’ve never believed or suggested you were poor. My reference to putting “ diesel” in your car was bought about by your nit-picking when someone said “petrol” yesterday. I withdraw the suggestion.

“agree ... still filling this years ISA allowance Ruck .... managed last years ok ... did you ?”
Do you remember the Harry Enfield character who kept saying “I am considerably richer than yow”?

Inan,
“Bermuda ... NDA ... Non Disclosure agreement ... ? exactly how can i answer you ?“

Are you suggesting the NDA that Scancell are under prevents them from disclosing ANYTHING to the market? Lol

Or are you suggesting that YOU are under an NDA yourself preventing you from answering any questions?
You haven’t disclosed any signs of sense so far!

...
Especially as you can’t afford the money for diesel to get there.

Inan,
I have only ever asked one question at an AGM..

Q. Will you issue an RNS when the first patient has been dosed?
A. Yes.

The Q&A in total took 17 seconds and I believe was useful to many investors.

I’m not sure why you feel you need to be the AGM question prefect?

Inan,
Forget IP, NDA etc. Think about the situation with the SCIB1 (our most advanced platform) which officially is “in the clinic”.

Has the trial been put on hold
Or
Is it proceeding as normal
Or
Is it Proceeding but slower than expected.

Thats not too complicated for a comment from the company surely?

I agree, an individual PI asking the CSO what’s going on and reporting back to a BB is not the way to do it.
What we need is proper communication from the CEO using the correct channels so all investors have the same information at the same time.

We have precious little information since the 19th August 2019 announcement that UK trials were to start “immediately”.

I sincerely hope we get some communication BEFORE the next AGM. if not, it’s the responsibility of the BOD to decide what answers they can give, not the responsibility of investors to decide what they can ASK.

Sorry about that Bunsie, I deserted my post.

Inan,
Well done you!
No excuses for not understanding the environment required for R&D then :)

Inan,
Your 11:11 is a classic example of your “if I can’t understand it, it must be wrong” attitude.
Obviously you have never run an R&D team.

Bunsie,
At 3p I might be tempted myself!

Well it seems like someone has struck a chord with some and hit a nerve with others.
I think an important point has been raised concerning the conflict between academia/science and commerce/finance.

Running a company and making it financially successful requires management, discipline, adherence to regulations and focus.
The environment you need to be a good research scientist is the opposite. You need to be given free reign, think laterally and not be constrained by rules.
This is no ones fault, it is just the way it is. It does need recognising and managing though.

Bunsie,
Trouble is, every time I turn the record over I find you on the B side.

Inan, you asked “what good points”.....

I think the main one was engaging better and more broadly with the market. After all, it is the market that ultimately defines the value of the company (currently 5.35p)

So better communication to answer...

What’s the revised timetable for the SCIB1 combo trial?
What’s the revised timetable for the SCIB2 trial?
What’s the revised timetable for the MODI1 trial?
Any progress on MODI2?
Any news on the BioNTech collaboration?
Any news on funding?
What’s the revised timetable on getting some “great data”?
What is the revised timetable on “monetising assets”?
Any news on COVIDITY development?
Any news on COVIDITY funding?

Michael, I think you have assessed the company and mood of several investors very well.
As a startup, a company has a lot of optimism surrounding it and not a lot of negatives. It takes time to acquire negatives - results falling short of expectations, slipping timescales, withdrawal of significant investors, change of personnel, increased cash burn etc etc. I am talking about startups generally - Scancell have not suffered from all of the above, but certainly some.

It’s a bit like interviewing internal and external candidates for a job. You know all the weaknesses of the internal people but none of the external ones are going to point their’s out.

Crumbs,
Touché. I’ll give you that one!
We can surely agree on my other point that Prof Durrant is Scancells best PR asset?

Crumbs,
You are of course entitled to your opinion. How do you explain David Evans statement that not getting Prof Durrant to go full time With Scancell as his biggest failure?